Xavier C. Badoux

St George Hospital
Sydney, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.

Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.

Journal: Internal medicine journal

Published: January 06, 2026

The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry.

The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry.

Journal: Best practice & research. Clinical haematology

Published: August 14, 2023

Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.

Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 19, 2023

The clinical features, management and outcomes of lymphoma in pregnancy: A multicentre study by the Australasian Lymphoma Alliance.

The clinical features, management and outcomes of lymphoma in pregnancy: A multicentre study by the Australasian Lymphoma Alliance.

Journal: British journal of haematology

Published: December 12, 2022

Chronic lymphocytic leukaemia Australasian consensus practice statement.

Chronic lymphocytic leukaemia Australasian consensus practice statement.

Journal: Internal medicine journal

Published: November 30, 2022

Capturing the lived experiences of women with lymphoma in pregnancy: a qualitative study.

Capturing the lived experiences of women with lymphoma in pregnancy: a qualitative study.

Journal: Leukemia & lymphoma

Published: November 24, 2022

Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.

Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 12, 2022

Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study.

Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study.

Journal: HemaSphere

Published: August 15, 2022

Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.

Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 07, 2021

Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma.

Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma.

Journal: Blood advances

Published: April 29, 2020

Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.

Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.

Journal: Leukemia

Published: April 17, 2020

Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development.

Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development.

Journal: Advances in therapy

Published: July 04, 2017

Showing 1-12 of 23

Last Updated: 09/26/2026